BiotechTube
PeploBio

PeploBio

London, United Kingdom· Est.
peplobio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

PeploBio operates as a hybrid diagnostics and CRO services company, leveraging high-resolution mass spectrometry (HRAMS) and immunoassay platforms to support pharmaceutical clinical development, particularly in metabolic disease. Its flagship offering is a quantitative HRAMS assay for GLP-1 receptor agonists, developed in partnership with Kingston Analytical Services Toxicology (KAST), enabling precise drug level measurement in clinical trials. The company's model combines laboratory testing, assay development/validation, and biospecimen sourcing to serve the growing precision medicine and clinical research markets.

Metabolic DiseaseType 2 DiabetesObesityCardiometabolic Disease

Technology Platform

Quantitative High-Resolution Accurate Mass Spectrometry (HRAMS) for peptide therapeutic analysis; Integrated immunoassay platform including flow cytometry, ELISA, and cellular phenotyping; AI/ML integration for data analysis.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The explosive growth of the GLP-1 and incretin-based therapy market creates immediate, high demand for specialized bioanalytical services to measure these complex peptides in clinical trials.
The broader shift towards precision medicine and biomarker-driven development expands the need for sophisticated CRO partners with advanced assay and data analysis capabilities.

Risk Factors

Heavy reliance on the continued pharmaceutical investment in the GLP-1 drug class poses a concentration risk.
The company faces intense competition from large, global CROs and must scale its niche operations while maintaining stringent quality standards to retain its regulatory accreditations and client trust.

Competitive Landscape

PeploBio competes in the bioanalytical CRO space against giants like LabCorp, Q2 Solutions, and ICON, as well as specialized niche labs. Its differentiation lies in its focused expertise on complex peptide quantification via HRAMS and its agile, specialist service model. Success depends on outperforming larger players in service quality and technical depth for specific assay types.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →